Results 201 to 210 of about 285,971 (306)

Comparison of vasopressin-first weaning versus norepinephrine-first weaning in critically ill patients. [PDF]

Int J Clin Pharmacol Ther
Alshreef M, AbaAlkhayl H, Almdainy Q, Alshammari A, Alajmi S, Alruwaite S, Alqahtani E, Almalke R, Alonazi T.   +8 more
europepmc   +1 more source

Watertown, City of and Watertown Professional Firefighters Association, International Association of Fire Fighters (IAFF), New York State Firefighters Association, Watertown Federation of Labor, Local 191 (1999) [PDF]

, 1999

core   +1 more source

From Brain Health to Brain Economy

Brain Health, EarlyView.
Yongjun Wang
wiley   +1 more source

Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database

Clinical Pharmacology &Therapeutics, EarlyView.
Disproportionality analyses suggested a cardiovascular risk signal for romosozumab, while statistically significant associations were not found in the real‐world database studies. Therefore, a larger comparative study was necessary to examine this signal.
Hotaka Maruyama, Eiko Iwasa, Shinya Watanabe, Tomoaki Hasegawa, Kazuhiro Kajiyama, Taihei Tanaka   +5 more
wiley   +1 more source

Incidence and Predictors of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients at a Tertiary Academic Hospital in Indonesia: A Retrospective Cohort Study. [PDF]

Hosp Pharm
Fitrianti AE, Astuti A, Reyaan IBM, Hendrayana T, Rahmah SA, Anggadiredja K, Zazuli Z.   +6 more
europepmc   +1 more source

Modeling Supports Combinatorial Effects Between Pharmacological and Non‐Pharmacological Interventions to Prevent Opioid‐Induced Cardiac Arrest

Clinical Pharmacology &Therapeutics, EarlyView.
Few studies have quantified the effects of non‐pharmacological interventions (e.g., rescue breathing) in the setting of community opioid overdose. We extended a previously validated model for opioid antagonists by incorporating the mechanism of rescue breathing, and quantified combinatorial effects between rescue breathing and various formulations of ...
Bradlee Thrasher, John Mann, Anik Chaturbedi, Shilpa Chakravartula, Hamed Meshkin, Affan Affan, Alexander Galluppi, Ji Young Kim, Nigar Karimli, Yue Han, Zachary Dezman, Jeffry Florian, Zhihua Li   +12 more
wiley   +1 more source

Safe Staffing Standards for Pharmacy Technicians in Hospital Settings. [PDF]

J Mark Access Health Policy
Silva V, Joaquim JJ, Desselle S, Quaye S, Matos C.   +4 more
europepmc   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, EarlyView.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Continuing as Partners in Immunization: Building Immunization Confidence Through Communication, Education, and Resources. [PDF]

J Pediatr Pharmacol Ther
Girotto JE, Warminski S, Oz T, Hunter Fly J, Cavness AA, Kubes SE.   +5 more
europepmc   +1 more source